Why the study?
Hypertension often features metabolic abnormalities increasing cardiovascular risk, and the comparative effect of different antihypertensive combinations on the triglyceride-glucose index remained unclear.
Does a RAAS blocker plus thiazide/thiazide-like diuretic increase the triglyceride-glucose index compared to a RAAS blocker plus calcium channel blocker in hypertensive patients?
Population
157 hypertensive patients meeting eligibility criteria
Comparison
RAAS blockers plus thiazide/thiazide-like diuretics vs RAAS blockers plus CCBs
Design
Retrospective observational study
Key result
RAAS blocker plus thiazide/thiazide-like diuretic therapy was associated with a significantly higher TyG index compared to RAAS blocker plus CCB therapy (β=0.385) in hypertensive patients.
Authors
Loading...
Thiazide addition to RAAS blockade was associated with higher TyG index; hypothesis-generating for metabolic effects and requires prospective confirmation.
Observational (n=157)
No
Does a RAAS blocker plus thiazide/thiazide-like diuretic increase the triglyceride-glucose index compared to a RAAS blocker plus calcium channel blocker in hypertensive patients?
Mean Difference: 0.385 (95% CI 0.181–0.589)
Absolute Event Rate: 9.21% vs 8.95%
p-value: p=0.0003
In hypertensive patients, combining a RAAS blocker with a thiazide diuretic is associated with a higher triglyceride-glucose index and worse metabolic profile compared to a CCB combination.
Erarslan et al. (2026) conducted an observational in Essential hypertension (n=157). RAAS blocker plus thiazide/thiazide-like diuretic vs. RAAS blocker plus calcium channel blocker was evaluated on Triglyceride-glucose (TyG) index (β=0.385, 95% CI 0.181-0.589, p=0.0003). RAAS blocker plus thiazide/thiazide-like diuretic therapy was associated with a significantly higher TyG index compared to RAAS blocker plus CCB therapy (β=0.385) in hypertensive patients.